



UK Stem Cell Network

INAUGURAL UKSCN MEETING MANCHESTER

16th-17th SEPTEMBER 2025

CONFERENCE BOOKLET



UKSCN

Inaugural Meeting

University Place, Manchester

Tuesday 16th – Wednesday 17th September 2025



WELCOME TO MANCHESTER FOR THE RE-ESTABLISHMENT OF THE UK STEM CELL NETWORK!

THANK YOU FOR JOINING US

On behalf of the UK Stem Cell Network organising committee, we warmly welcome you to the inaugural UKSCN 2025 Meeting, taking place in Manchester. Your presence and support whether as a delegate, speaker, guest, exhibitor or sponsor are vital to the success of this event, and we are delighted to have you join us.

In bringing the UK stem cell research community together to re-establish a productive and inclusive national network we endeavour to provide an exciting programme, with plenty of opportunities to meet new and existing connections and promote opportunities for collaboration and innovation.

Please help us to achieve this by actively engaging with our speakers, contribute to the discussion sessions and provide your thoughts in our survey's and through feedback on the event. We really would like the network to represent what you need it to be, so please share your vision.

Our sponsors and exhibitors have provided vital support to enable this meeting to be as accessible to as many researchers as possible, so do please stop by and engage with them. Please also visit the poster presenters who will communicate their research during the Poster session on Tuesday evening between 17:30 and 18:30.

If you have opted into our Networking event at the Manchester Museum, kindly supported by **STEMCELL Technologies** and **Qkine**, this will be indicated on your conference badge with an image of a dinosaur skull. Please note this is a capped-ticketed event for Health and Safety reasons.

We do hope you have shared your views via our pre-meeting survey, results of which will be discussed in our remit session. This session is your opportunity to influence how the UK Stem Cell Network will be run for the community and what its priorities and activities should be. Please join us in this session and have your say to influence this. If you have not already done so, you are still welcome to complete the short survey which can be found here: <https://forms.gle/eDGesJQhRZd5prAK6>.

We thank you once again for being part of this important occasion and look forward to meeting you in Manchester.

Warm regards,

The UK Stem Cell Network Organising Committee

ukstemcellnetwork@gmail.com

PS – Don't forget to look out for your badge buddies. How many new connections can you make this meeting?

Inaugural Meeting
University Place, Manchester
Tuesday 16th – Wednesday 17th September 2025



THANK YOU TO OUR MEETING SPONSORS!

Platinum Sponsors and Exhibitors

Qkine



Gold Sponsors and Exhibitors



Gold Sponsor




Silver Sponsors and Exhibitors

<p>Conference Bag Sponsor</p>  <p>amsbio Part of Europa Biosite</p>	 <p>BIOCAIR®</p>	 <p>CATAPULT Cell and Gene Therapy</p>	 <p>EBISC European Bank for Induced pluripotent Stem Cells</p>
<p>Haier Biomedical</p> <p>Intelligent Protection of Life Science</p>	 <p>IDT INTEGRATED DNA TECHNOLOGIES</p>	<p>Best Poster Sponsor</p>  <p>MERCCK</p>	 <p>Nikon</p>
 <p>PHCBI</p>	 <p>PARSE BIOSCIENCES</p>	 <p>PeptiMatrix™ Next generation peptide hydrogels</p>	
<p>Lanyard Sponsor</p>  <p>Regen CTC</p>	 <p>proteintech®</p>	 <p>StemTech</p>	
	 <p>stemgenomics cell integrity</p>	 <p>UK Stem Cell Bank</p>	

Bronze Sponsors

 <p>bit.bio THE CELL CODING COMPANY</p>	<p>Best Oral Presentation Prize Sponsor</p>  <p>MARRABIO</p>	 <p>Rinri Therapeutics</p>
 <p>Roslin^{CT} your advanced therapy solution</p>	 <p>Swift Analytical Life Science Technologies</p>	 <p>tcs biosciences</p>



Stand No. Company

- 1 iotaSciences
- 2 ProteinTech
- 3 Biocair
- 4 Bio-Techne
- 5 IDT DNA
- 6 Haier Biomedical
- 7 amsBio
- 8 Medicines and Healthcare
Products Regulatory Agency
- 9 Regen CTC
- 10 ThermoFisher Scientific
- 11 Nikon Healthcare
- 12 Parse Biosciences
- 13 PHC Europe B.V.
- 14 Qkine
- 15 STEMCELL Technologies
- 16 Peptimatrix
- 17 Oxford Stem Tech
- 18 European Bank for iPSCs (EBiSC)
- 19 Merck Life Science
- 20 Stem Genomics



Lift



Power Point



Fire Call Point



Poster Boards

Scale

□ = 1m

1cm = 4m
when printed at A4

Please note due to ongoing maintenance - toilets located on 1st, 2nd, 3rd and 4th floors

Inaugural Meeting

University Place, Manchester


Tuesday 16th – Wednesday 17th September 2025



Tuesday 16th September 2025

11:00	Registration Opens (Drum)
11:00 – 13:00	Poster Set-up & Exhibition Hall open with Refreshments sponsored by AMSBio and The UK Stem Cell Bank

12:00- 13:00 (Drum & Market Place)	11:30 - 12:15 (Lecture Hall)
Buffet lunch sponsored by	Translating Research..... What does it take? An intro session
Biocair, Proteintech and Stem Genomics	Terri Gaskell, CTO Rinri Therapeutics Davide Danovi, CSO Migration Biotherapeutics Matthew Smart, CGT Catapult

Lecture Hall	Welcome session - chaired by Sue Kimber and Owen Harrison	Sponsored by: ThermoFisher Scientific
13:00- 13:10	Welcome address	Peter Andrews Emeritus Professor
Keynote Address		
13:15-13:45	Creating a functional human thymus from scratch: a stem cell story in the times of multi-omics.	Paola Bonfanti, The Francis Crick Institute, London
13:50-14:10	Harnessing human pluripotent stem cells to model and treat Parkinson's disease	Tilo Kunath, University of Edinburgh
14:15-14:35	Understanding and overcoming stem cell differentiation bias	Magdalena Sutcliffe, LMB Cambridge
14:40-14:50	Integrating AI into Our Understanding of Cell Fate and State	Owen Rackham, University of Southampton
14:55-15:05	Gastruloids "Over Easy": building better models of early human development	Timothy Grocott, University of East Anglia
15:10-15:25	Advancing Neurological and Retinal Research with Genetically Diverse Human iPSC-Derived Cellular Models.	 Andrew Gaffney, Stem Cell Technologies

15:30-16:00 Coffee break with Networking sponsored by Haier Biomedical and Parse Biosciences:

Lecture Hall	Session 2 chaired by Nick Hannan and Anzy Miller	Sponsored by: Biotechne
16:00-16:20	Reconstruct human embryonic cell fate transition using stem cell models	Ge Guo, University of Exeter
16:25-16:45	Epithelial stem cells and airway regenerative medicine.	Robert Hynds, University College London

Inaugural Meeting

University Place, Manchester

Tuesday 16th – Wednesday 17th September 2025



Lecture Hall	Session 2 chaired by Nick Hannan and Anzy Miller	Sponsored by: Biotechnie
16:50-17:00	A novel hiPSC-derived immune competent alveolar organoid xeno-free model to study homeostasis and injury repair mechanisms	Carlos B. Sainz Zuñiga, University of Nottingham
17:05-17:15	The Role of Caveolin-1 in the Selective Advantage of genetically variant human pluripotent stem cells	Haneen Alsehli, University of Sheffield
17:20-17:30	Functional and molecular rescue of aganglionic colon by human enteric nervous system progenitor transplantation in Hirschsprung disease	Benjamin Jevans, University College London

17:30-19:00 *Poster session with networking drinks and canapes (sponsored by Qkine & Stem Cell Technologies) within the exhibition hall (Drum and Market Place)*

19:00 - Evening Networking at the Manchester Museum Fossils/Living Worlds Gallery, Oxford Road, Manchester M13 9PL

Continue the evenings networks with grazing platters, entertainment and drinks kindly provided by our Principal sponsors **Qkine** and **Stem Cell Technologies** surrounded by the wonders of the Fossils and Living Worlds exhibits at Manchester Museum.

Qkine



In addition to your two drinks vouchers, there will also be a cash bar.



This was an opt-in ticketed event during registration, which is restricted in its capacity for Health and Safety.

Please do not try to enter if you haven't registered.

Inaugural Meeting

University Place, Manchester

Tuesday 16th – Wednesday 17th September 2025



Wednesday 17th September 2025

08:00-08:50	Classroom 1.219 (University Place level 1) Meet the Experts – ECR Breakfast (9 tables of 10) Sponsored by: Biotechne, IotaSciences, ThermoFisher Scientific and WiCell
-------------	---

Lecture Hall	Session 3 chaired by Patrizia Ferretti and Amal Khizer		Sponsored by: IotaSciences
09:00-09:20	The epigenetic-metabolic crosstalk in pluripotent stem cells		Yaser Atlasi, Queen's University Belfast
09:25-09:45	Stem cell models to unpick cardiovascular disease and evaluate drug safety		Chris Denning, University of Nottingham
09:50-10:00	Modelling Human Growth Plate Cartilage Using Pluripotent Stem Cells		Steven Woods, University of Manchester
10:05-10:15	Active WNT/ β -Catenin signalling derails the naïve to primed state transition in human pluripotent stem cells		Connor Ross, University of Aberdeen
10:20-10:30	Targeting the Leukemia Bone Marrow Microenvironment (BME)		Ranudi Kudellage, University of Bristol
10:35-10:45	Examination of the circadian rhythms in retinal organoids derived from iPSCs from patients with bipolar disorder		Sally Harwood, Newcastle University
10:45-11:00	Commercial media formulations vs chemically defined home-brewed media for iPSC maintenance	Qkine	Liz Stewart Qkine

11:00-11:30	Coffee break with Networking in the Drum & Market Place sponsored by Nikon and Oxford Stem Tech
-------------	--

Lecture Hall	Session 4: Establishing a UK Stem Cell Network – Defining Our Remit	
11:30-12:45	Our Vision for a UKSCN – Have your Say! Interactive session led by Ivana Barbaric, James Henstock and Adam Hirst With guest panellists Jon Draper (SCN, Canada), John de Vos (FSSCR, French Society for Stem Cell Research), Owen Harrison (London Stem Cell Network (LSCN)) and Sue Kimber (Mercia Stem Cell Alliance (MSCA))	

Inaugural Meeting

University Place, Manchester

Tuesday 16th – Wednesday 17th September 2025



12:45-14:30 (Drum)	13:15-14:00 (Lecture Hall)
<p>Keeping the conversations going: Opportunities to engage with the team and share your views, visit the posters or engage with the exhibitors! Can you find your Badge Buddies??</p>	<p><i>Translating Research..... Where are we now and what have we learnt?</i></p>
	<p style="text-align: center;"><i>Sponsored by:</i> <i>Cell and Gene Therapy Catapult and Regen CTC</i></p>
<p><i>Lunch Sponsored by Integrated DNA Technologies, PHcbi and PetiMatrix</i></p>	<p><i>Case Study presentations by</i> <i>Terri Gaskell, CTO Rinri Therapeutics</i> <i>Davide Danovi, CSO Migration Biotherapeutics</i></p>
	<p><i>Joined by Panellists</i> <i>Zoe Hewitt, Regen CTC</i> <i>Matthew Smart, CGT Catapult</i></p>

Lecture Hall	Session 5 chaired by: Amanda Carr and Lyn Healy	Sponsored by: WiCell
14:30-14:35	The Pete Coffey Award – The Man behind the Award	Fionn Coffey
14:40-14:55	Winner of the Pete Coffey Award for Best Submitted Abstract Patient-specific iPSC models of neural tube defects identify underlying deficiencies in neuroepithelial cell shape regulation and differentiation	Ioakeim Ampartzidis University of Cambridge
15:00-15:20	Ex vivo blood stem cell expansion: technology to biology	Adam Wilkinson, Cambridge Stem Cell Institute
15:25-15:45	Oscillatory expression of transcription factors controls the timing of differentiation	Nancy Papalopulu, University of Manchester
15:45-16:00	Next steps for the UKSCN and Awards presentation	Ivana Barbaric, University of Sheffield Nick Hannan, University of Nottingham
16:00	Meeting closes	

The UKSCN Inaugural Meeting organisers wish to express their thanks to the Principal Sponsors, Qkine and STEM CELL Technologies and all the other sponsors, exhibitors and supporters, without whom this meeting would not have been possible.

Please take the time to visit the exhibition hall and engage with the exhibitors, as we simply cannot put on meetings that are affordable for delegates without their support.

Thank you



Raising **the standard** in bioactive protein manufacturing and innovation

Growth factors and cytokines tailored for stem cell and organoid culture

All our products rigorously adhere to our **Nine-point Qkine Quality Commitment**

- ▶ Robust animal-free manufacturing platform
- ▶ Reproducible and reliable to optimize scientific outcomes
- ▶ Unique optimized proteins to address fundamental biological, translational and scale challenges
- ▶ Accessible and knowledgeable science-led team

Proactive support for emerging fields such as cellular agriculture, regenerative medicine, synthetic hydrogels, organ-on-a-chip technology and bioprinting.



We're here to help you achieve successful and stress-free science
customerservice@qkine.com



Qkine Ltd, Unit 1, Murdoch House, Garlic Row, Cambridge, CB5 8HW
www.qkine.com | +44 (0) 1223 491 486 | +1 866 877 2185
Qkine products are for research use and ex vivo cell manufacturing use only

Image credit: Neurons derived from ES cells. Steven Pollard. Attribution 4.0 International (CC BY 4.0)



High-Quality, Genetically Diverse Human iPSC Lines for Reliable Research

Discover SCTi005-A (female) and SCTi006-A (male) hiPSC lines, derived from PBMCs using Sendai Virus reprogramming and optimized for TeSR™ maintenance and STEMdiff™ differentiation.



View Products

www.stemcell.com/ipscs

Copyright © 2025 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, Scientists Helping Scientists, and STEMdiff are trademarks of STEMCELL Technologies Canada Inc. TeSR is a trademark of WARF. All other trademarks are the property of their respective holders.



Scientists Helping Scientists™ | WWW.STEMCELL.COM

Speaker Bios – Session 1



Prof Peter Andrews
Emeritus University of
Sheffield

Peter Andrews obtained a BSc in Biochemistry from the University of Leeds in 1971, and a D.Phil. in Genetics from the University of Oxford in 1975. Following postdoctoral research at the Institut Pasteur in Paris and the Sloan Kettering Institute in New York, he was a research scientist at the Wistar Institute in Philadelphia from 1978 to 1992 where he characterised the properties of human embryonal carcinoma (EC) cells, the malignant counterparts of human embryonic stem (ES) cells. From 1992 to 2020 he held the Arthur Jackson Chair of Biomedical Research in the University of Sheffield, with research focused on the biology of ES cells. From 2003 to 2018 co-ordinated the International Stem Cell Initiative and from 2014 to 2018 he directed the Pluripotent Stem Cell Platform, a Hub of the UKRMP. He is currently Professor Emeritus at the University of Sheffield.

KEYNOTE



Prof Paola Bonfanti
The Francis Crick Institute

Paola Bonfanti is a Group Leader at the Francis Crick Institute and Professor of Epithelial Cell Biology & Regenerative Medicine at University College London. She received her MD from the University of Milan and a PhD from EPFL in Lausanne, specializing in epithelial stem cell biology under the supervision of Yann Barrandon. Supported by a Long-Term EMBO fellowship and a Young Investigator Award from the EFSD/JDRF/Roche, she trained in regenerative medicine and reported the existence of adult pancreatic progenitors contributing to organoid research.

In 2014, she established her laboratory with a UCL-Rosetrees Excellence Fellowship. The following year, she secured an ERC Starting Grant for her research on thymus biology. Her work led to the first identification of multipotent stem cells in the thymus and the reconstitution of a functional human thymus. She has recently received major funding from the MRC and ERC, to investigate the regenerative potential of the thymus in ageing and disease using an integrative biology approach. Her research combines stem cell biology and bioengineering technologies to develop advanced 3D in vitro models for various epithelia including oesophagus and airways.



Prof Tilo Kunath
University of Edinburgh

Tilo Kunath obtained his PhD from the University of Toronto in 2003 investigating novel stem cell systems. His postdoctoral studies at the Institute for Stem Cell Research at the University of Edinburgh were focused on neural induction and differentiation of pluripotent stem cells. In 2007 he started his laboratory with a Parkinson's UK Senior Fellowship at the MRC Centre for Regenerative Medicine in Edinburgh. He has pioneered the use of patient-specific induced pluripotent stem cell (iPSC) technologies to establish robust models of Parkinson's to investigate disease mechanism, and for use in cell replacement therapies.

Speaker Bios – Session 1



Dr Magdalena Sutcliffe
MRC Lab of Molecular
Medicine

Magdalena Sutcliffe is the Research Support Manager at MRC Laboratory of Molecular Biology, University of Cambridge. Magda obtained her PhD from Peninsula Medical School investigating new therapeutic target in nervous system tumours. In 2015 she joined the Lancaster Lab at the MRC LMB. Her research interests focus on stem cell and brain organoid method development, scaling up and optimization of culture methods, and epigenetic basis of fate transitions.



Owen Rackham
University of Southampton

Submitted Abstract Speaker

Owen Rackham is an Associate Professor at the University of Southampton, leading the data-driven biology group. His group's primary interest is in what defines human cells and how their phenotype emerges from the complex interplay between the genome, transcriptome and environment. His team combines data generation with computational methods to develop predictions about how specific perturbations or conditions can influence a cell's fate, using this technique to deepen our understanding of cell fate reprogramming.



Timothy Grocott
University of East Anglia

Submitted Abstract Speaker

Timothy Grocott is a PI at the University of East Anglia (UEA), where his group is interested in the role of self-organising processes during early development of various organ systems including the eye, brain and heart. The Grocott lab use a combination of human iPSC and chick embryo experimental models together with computational modelling in their research.



Andrew Gaffney
STEMCELL Technologies

Principal Sponsor Talk

Dr. **Andrew Gaffney** is the Director of Stem Cell Manufacturing and Commercialization at STEMCELL Technologies, where he oversees the development of human iPSCs, differentiated cells, and organoids. Andrew completed his PhD in pediatric oncology at the University of Leeds where he successfully established a human embryonic stem cell disease model of Ewing sarcoma. After joining STEMCELL in 2014, Andrew managed the company's pluripotent stem cell product portfolio. He has also developed strategic alliances with stem cell scientists in academia and industry to support the development of PSC-based disease models, drug screens, and cell therapy applications.

THE **NEW** CLONING PLATFORM XT

GET A FULL 96-WELL PLATE OF VERIFIED MONOCLONAL CULTURES WITH **RELIABLE, HIGH-QUALITY RESULTS – FAST!**

APPLICATIONS

-  GENE EDITING
-  CELL LINE DEVELOPMENT
-  CHO / iPSCs / hESCs
-  REPORTER CELL LINES

TRUSTED TECHNOLOGY BY LEADING R&D GROUPS WORLDWIDE



KEY BENEFITS

- Delivers full plates of verified monoclonal cultures
- Fully automated workflow from single-cell isolation to delivery of clones
- AI-powered rapid single-cell verification
- Documented monoclonality assessment report



...or contact us at: sales@iotasciences.com

Learn more at: <https://iotasciences.com/cloning-platform-xt-2>

 Medicines & Healthcare products Regulatory Agency

Quality assured stem cells

The UK Stem Cell Bank, from the Medicines and Healthcare products Regulatory Agency, is a world-leading resource for ethically sourced, high quality, human embryonic stem cell (hESC) lines for research and clinical applications.

Apply for quality assured cell lines


We hold most UK-derived hESC lines, alongside several cell lines from depositors worldwide. New high quality cell lines are added regularly.

Our hESC lines are compliant with regulations from the UK Human Tissue Authority, and the Human Fertilisation and Embryology Authority.

nibsc.org/ukstemcellbank



Scan the QR code or visit our website to view our cell lines catalogue



 UK Stem Cell Bank

stemgenomics
cell integrity



Just send DNA by post and we'll take it from there!

3 days

to ensure the quality and reproducibility of your research work.

3 seconds

to understand the results

A 3-in-1 service

Benefit from a 3-in-1 service from the same sample*:

- Human cell line authentication
- Digital PCR karyotype
- Mycoplasma detection



Your time is precious, let's get started.

Contact us to implement this cost-effective and reliable quality control used by major players in the field of human stem cells.

Stem Genomics - Next Generation Quality Control for Cell Therapy
stemgenomics.com

*Possibility to add G-Banding and pluripotency/differentiation monitoring to create a 5-test package ! (with extended lead times)

Speaker Bios – Session 2



Dr Ge Guo

University of Exeter

Ge Guo is a senior research fellow and a principal investigator at the Living System Institute, University of Exeter, UK. She is one of the pioneers in the establishment and validation of human naïve pluripotent stem cells.

In her recent research, Dr Guo discovered the trophectoderm differentiation potential of human naïve pluripotent stem cells, which led to the establishment of integrated human embryo models. Her current research is centred on understanding the regulatory mechanism of pluripotency and cell fate transition during early human embryogenesis.



Robert Hynds

University College London

Rob Hynds is based at the University College London (UCL) Great Ormond Street Institute of Child Health, where he leads the Epithelial Cell Biology in ENT Research Group (EpiCENTR). The group's research focuses on epithelial stem cell biology, with particular interests in regenerative medicine and disease modeling in the human airway.

Rob completed his PhD at UCL, where he developed novel in vitro models of the airway epithelium. As a postdoctoral researcher at the Francis Crick Institute, he used patient-derived models to investigate lung cancer evolution and therapy resistance. Since establishing his independent research group in 2022, Rob has led efforts to develop pro-regenerative therapies for lung diseases, including gene-corrected epithelial cell therapies for rare airway diseases such as epidermolysis bullosa.

Rob leads the pre-clinical models core within the CRUK Lung Cancer Centre of Excellence and was committee chair of the London Stem Cell Network from 2019-2023.



Carlos B. Sainz Zuñiga

University of Nottingham

Submitted Abstract Speaker

Carlos B. Sainz Zuñiga, is a PhD student in the Hannan Lab at the University of Nottingham. His research focuses on the development of hiPSC-derived organoid models to study health and disease.



Haneen Alsehli

University of Sheffield

Submitted Abstract Speaker

Dr Haneen Alsehli completed her PhD at KCL, where she studied how physical confinement influences differentiation in hiPSC spheroids using high-content analysis. She is currently a postdoctoral research associate at the University of Sheffield, investigating the role of mechanosensing at cell–ECM adhesions in hPSC.

Inaugural Meeting

University Place, Manchester

Tuesday 16th – Wednesday 17th September 2025



Speaker Bios – Session 2



Benjamin Jevans

University College London

Submitted Abstract Speaker

Dr Ben Jevans is a post-doctoral research fellow at UCL Great Ormond Street Institute of Child health. He is interested in the development of the enteric nervous system, including how it connects to the central nervous system via the gut-brain axis and how it is affected by childhood diseases.

Best Oral Presentation Prize

Submitted abstract speakers are all eligible for the Best Oral Prize, Sponsored by MarraBio and the UKSCN. These prizes are being judged by a panel of registered experts and will be awarded at the end of the meeting.



Best Poster Presentation Prize

All our poster presenters (non-sponsors) are eligible for the Best Poster Prize, Sponsored by Merck and the UKSCN. These prizes are being judged by a panel of registered experts and will be awarded at the end of the meeting.



Speaker Bios – Session 3



Yaser Atlasi

Queen's University Belfast

Dr. Yaser Atlasi is a Senior Lecturer at the Patrick G. Johnston Centre for Cancer Research at Queen's University Belfast. His research focuses on the mechanisms of epigenetic regulation in stem cells and cancer. Dr. Atlasi obtained his PhD in Molecular Medicine from ErasmusMC in the Netherlands and completed postdoctoral training in epigenomics and functional genomics at Radboud University under the mentorship of Professor Henk Stunnenberg.

In 2020, he established his independent research group, which investigates stem cell epigenetics, with a particular focus on the interplay between WNT and FGF/ERK signalling and chromatin regulation. His team explores how disruptions in these mechanisms contribute to cancer development, utilizing various stem cell models combined with state-of-the-art genomics, proteomics, and computational biology approaches. Their goal is to make fundamental discoveries that can ultimately address important health challenges within society.



Chris Denning

University of Nottingham

Chris Denning is Professor of Stem Cell Biology and Director of the Biodiscovery Institute (BDI). The £100m Institute is the largest research facility at the University of Nottingham and houses 850 researchers, clinicians and support staff. Research is across 6 themes of global importance, encompassing Cancer, Engineering Biology, Pioneering Therapeutics, Regenerating & Modelling Tissues, Taming Microbes, and Demystifying Biomolecular Complexity.

Spanning several of BDI's themes, Chris' interests are in cardiovascular differentiation of human pluripotent stem cells (hPSCs: human embryonic stem cells [hESCs] and human induced pluripotent stem cells [hiPSCs]) for use in drug screening and in production of new in vitro models of genetic-based cardiovascular disease.

Submitted Abstract Speaker



Steven Woods

University of Manchester

Steven Woods is a postdoctoral researcher at the University of Manchester and has developed a lab-grown model of human growth plate cartilage and, using single-cell RNA sequencing, shown it closely mirrors real human development. He has used this model to uncover the causes of cartilage diseases and is now using it for drug screening.

Submitted Abstract Speaker



Connor Ross

University of Aberdeen

Connor Ross is a BBSRC postdoctoral researcher (Molecular developmental biologist) at the University of Aberdeen with interests in WNT signalling governing early human embryogenesis, fertility and reproduction.

Speaker Bios – Session 3



Ranudi Kudellage
University of Bristol

Submitted Abstract Speaker

Ranudi Kudellage is a postgraduate researcher completing her Masters by Research degree in the 3RsLab on Stem Cell Microenvironment, University of Bristol. Currently working with Dr. Pal on advancing a 3D bio-printed, human stem cell derived bone marrow platform to co-culture leukaemia cells and find new druggable targets.



Sally Harwood
Newcastle University

Submitted Abstract Speaker

Sally Harwood is a PhD student at Newcastle University investigating circadian rhythms in bipolar disorder. Previously, Sally studied a BSc in medical genetics and MSc in translational neuropathology at the University of Sheffield. She then spent time working in a HTT diagnostics lab in Germany before returning to academia.



Lize Stewart
Qkine

Principal Sponsor Talk

Liz Stewart is Head of Marketing and Scientific Communications at Qkine, a Cambridge-based manufacturer of high-quality bioactive growth factors and cytokines for stem cell research. She holds a PhD from the University of Nottingham and has over a decade of research experience in neovascular eye diseases, including eight years of postdoctoral work on primary cell-based ex vivo models of disease progression.

Previously, Liz was Principal Scientist at Exonate, leading R&D on small molecules for splicing control in neovascular disease, cancer, and inflammation, advancing candidates into Phase I/II clinical trials. At Qkine, she combines scientific expertise with communication strategy to create impactful content and foster collaborations with researchers in biotech and academia.

DID YOU KNOW

WE HAVE A PSC SCALE-UP SOLUTION FOR YOUR PROCESS DEVELOPMENT WORKFLOW?

Gibco™ StemScale™ PSC Suspension Medium is a scalable, easy-to-use medium that supports robust expansion of pluripotent stem cells (PSCs) in suspension.



Find out more at thermofisher.com/stemscale

For Research Use Only. Not for use in diagnostic procedures. © 2021 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. COL25812 1121

gibco



EBiSC®

The European Bank for iPSCs

950+ iPSC lines

45+ diseases

Isogenic cohorts

Familial controls



iPSC services

www.EBiSC.org

StemTech
POWERING PRECISION MEDICINE

OUR EXPERTISE

Our **ReproPlex™** platform powers scalable iPSC reprogramming. Accelerate insights with multi-donor validation and discover tomorrow's medicine. From a wide-range of primary cells, we make iPSC, organoids amongst several other cell types. We are your partners for drug discovery and in-vitro disease modelling.



OUR IMPACT

- 25+ Academic and Big Pharma clients and partnerships.
- 1000's of high quality, genomically stable iPSC lines rapidly generated, underpinning ground-breaking research
- 10+ validated and reproducible disease models, accelerating drug discovery programs

DISCOVER MORE AT

oxfordstemtech.com



Scan for more information

Speaker Bios – Session 5

Pete Coffey Award Winner



Ioakeim Ampartzidis
University of Cambridge

Dr Ioakeim Ampartzidis completed his PhD at UCL in the Neurulation Biomechanics (Galea) Lab, where he developed disease modelling platforms for studying spina bifida. Currently he is working as a postdoctoral research associate in the Hollfelder Lab at the University of Cambridge, studying planar cell polarity signalling during early embryonic development.



Adam Wilkinson,
Cambridge Stem Cell
Institute

Dr. Adam Wilkinson is the Krishnan-Ang Group Leader in Haematology within the Cambridge Stem Cell Institute and Department of Haematology, University of Cambridge. Between 2021 and 2025, Dr. Wilkinson was a group leader at the MRC Weatherall Institute of Molecular Medicine at the University of Oxford and previously performed postdoctoral training at Stanford University and the University of Tokyo.

Dr. Wilkinson's research focuses on blood stem cells, which have the unique ability to regenerate the entire blood system and are used clinically in stem cell transplantation therapies. He has pioneered novel polymer-based methods to expand transplantable blood stem cells long-term ex vivo. His current research focuses on the translational applications of this ex vivo blood stem cell culture technology and better understanding the molecular regulation of blood stem cell activity.



Nancy Papalopulu,
University of Manchester

Nancy Papalopulu did her PhD at the National Institute for Medical Research, UK with Rob Krumlauf on the role and regulation Hox genes, followed by a post-doc at the Salk Institute for Biomedical Research, US with Chris Kintner on Xenopus neural development. She was a Group Leader at the Gurdon Institute, Cambridge, UK, for 10 years and then moved to the University of Manchester in 2006 to take up a Professorship in Developmental Neuroscience. She was a Wellcome Trust Senior Research Fellow for 15 years and is now a Wellcome Trust Investigator.

Prof. Papalopulu is an elected member of EMBO and a Fellow of the Academy of Medical Sciences. Her work combines experimentation, in particular quantitative and dynamic imaging, with theoretical modeling to understand how cells make fundamental cell state transitions during the development of the vertebrate central nervous system, using several model systems.

Speaker Bios – Session 5



Ivana Barbaric
University of Sheffield

Ivana Barbaric is a Professor of Stem Cell Biology at the University of Sheffield. Her research is focused on the basic biology of human pluripotent stem cells (hPSCs) and their applications in regenerative medicine and disease modelling. In particular, her group is investigating the causes and consequences of aneuploidy in stem cells, including the impact of aneuploidy on stem cell fate decisions and lineage specification during early development. Her work on culture-acquired genetic changes in hPSCs is also informing strategies for reliable detection and minimising the occurrence of genetically variant cells, necessary for safe and efficient clinical translation of hPSC-based therapies. Ivana is a member of the Steering Committee of the International Stem Cell Initiative, the General Secretary of the British Society for Gene and Cell therapy and was a member of the ISSCR Task Force on Standards for Stem Cell Research, co-chairing the Working Group on Genomic Characterization of Stem Cells.



Nick Hannan
University of Nottingham

Nick Hannan is an Associate Professor of Translational Stem Cell Biology based at the University of Nottingham's Biodiscovery Institute. His lab develops human stem-cell-derived models of endodermal organs — especially liver, intestine, pancreas, and lung— to study development and disease, including pulmonary fibrosis, fatty liver disease and inflammatory bowel disease. He has developed widely used, chemically defined animal-free protocols resulting in multiple patents and a spin-out companies that utilise the technology. He is course director for the University of Nottingham's MSc in Stem Cell Technology and Regenerative Medicine and leads the Regenerating and Modelling Tissues community within the School of Medicine.

biotechne®




- Research grade microscope in a ready-to-use benchtop lab instrument
- AI trained giving effortless results
- Acquisition and analysis settings autonomously found by the system
- Intuitive usage means no training is required
- Prevents inaccurate interpretation of data due to incorrect acquisition settings or analysis



SCAN ME

Visit our website to find out more and read application notes for all available assays



More assays available!

Connect with us




For more information contact:

Sanju.ashraf@nikon.com



Struggling to differentiate your stem cells? Try PerLAM™

Perlecan is a key basement membrane protein that acts as both a structural and signaling hub. Through its heparan sulfate (HS) chains, it binds growth factors like bFGF and interacts with matrix components to regulate cell growth, communication, and differentiation, transforming the matrix into an active, instructive environment.



When linked with our iMatrix Laminin E8 fragments, perlecan creates a next-generation matrix called P-Laminin E8 (PerLAM™). The matrix promotes cell adhesion via integrin binding (Laminin E8) and signalling power via growth factor binding (Perlecan).

- Strong integrin binding anchors cells securely
- Heparan sulfate chains promote growth factor signalling
- Improves culture stability and long-term cell survival
- Retains full functionality after refrigerated storage

Laminin E8 fragment: integrin binding sites ensure strong and specific adhesion to cells.

Perlecan domain I: contains Heparan sulfate domains that capture growth factors at the cell surface.

Dual-function surface: the combined result is a matrix that supports both mechanical anchoring and biochemical signaling.

Perlecan PDI + Laminin E8 = PerLAM™

www.amsbio.com

Translating Research.....What does it take and what lessons can we learn?

Session 1 – Tuesday 16th 11:30 - 12:15 – An Introduction to Translation

Session 2 – Wednesday 17th 13:15-14:00 – Case Study Discussed

Both Session will run in the Lecture Hall


Rinri Therapeutics – Case Study



Dr Terri Gaskell
Chief Technology Officer

Terri has over 20 years of life sciences R&D experience in both academic and industry roles with a focus on the development and translation of cell- and gene-based therapies. Before joining Rinri, Terri worked at the Cell and Gene Therapy Catapult for over seven years on the translation of a broad range of candidate therapies, including stem cell derived, alongside underpinning technologies and infrastructure. Her role at CGT Catapult also included advising academics and small companies on the development of advanced therapies.

Prior to this, Terri held senior roles in industry focussed on the development of processes for the expansion and differentiation of pluripotent stem cells for therapeutic use and drug discovery. Terri received her BSc. (Hons) in Biochemistry from the University of Dundee and holds a PhD in Cell and Molecular Biology from the University of Edinburgh.



Dr Matthew Smart
Lead Scientist


Cell and Gene Therapy Catapult

Matthew has been working in the pluripotent stem cell field for over 15 years. He gained his PhD at The Institute of Ophthalmology, University College London, as part of the London Project to Cure Blindness group, which developed a hESC-RPE-based cell therapy for AMD that showed great promise in FiH clinical trials. As a Lead Scientist at Cell and Gene Therapy Catapult, Matthew is active across all aspects of cell therapy translation, with specific expertise in pluripotent stem cell therapies. The SET team aims to develop next-generation manufacturing strategies for cell and gene therapy production, while helping to foster an environment that can best support developers as they move towards the clinic and beyond.



Dr Davide Danovi
Migration Biotherapeutics

Davide brings his experience and passion in cross-sector projects bridging academia and biotech. He has visiting roles at King's College London (where he previously led the HipSci Cell Phenotyping group) and at University of Cambridge (at the Stem Cell Institute). He has several years of experience in human stem cells characterisation based on high content imaging. He is co-founder CSO of Migration Biotherapeutics and an independent partner with Hoya Consulting. Formerly Director of Phenotyping in bit.bio, Davide is an MD PhD and part of the FLIER (Future Leaders for Innovation Enterprise and Research) group at the Academy of Medical Sciences.



Dr Zoe Hewitt
Regen CTC

Zoe has a background in Pluripotent Stem Cells, which started in 2001 when she obtained her PhD from the Roslin Institute/ University of Edinburgh. After completing her studies, she worked with a team developing differentiation protocols for hepatocytes, before moving to the University of Sheffield in 2006, where she established and managed a clean room facility, responsible for deriving the UKs first clinically available hESCs (MasterShef lines 1 to 14). Within this facility, Zoe and her team were responsible for delivering the starting master cell banks (Shef1) for the London Project to Cure Blindness. This resulted in the first successful UK clinical trial of an hPSC-derived retinal pigment epithelium (RPE) cell replacement therapy.

In 2022, established Regen CTC, a consultancy company that offers support to ATMP developers as they transition from innovation to product development.

Navigating the
journey from bench
to bedside



We are

A network of UK academic experts with real world experience of translating advanced therapies to the clinic.

We have

The knowledge and experience to accelerate your cell and gene therapy developmental pipeline, helping you to avoid common pitfalls.

This includes expertise in designing, developing and implementing:

- ***Document management***
- ***Lab efficiency management***
- ***Developing quality management systems***
- ***Process development of research protocols***
- ***Cleanroom management and operations***

Our goal

To assist advanced therapy developers to deliver their complex therapies to the clinic in order to benefit the patients who need them.



Find us:
www.regenctc.com

Contact us:
info@regenctc.com
0114 3767282

Inaugural Meeting

University Place, Manchester

Tuesday 16th – Wednesday 17th September 2025



UK Stem Cell Network

Meet the Experts Early Career and Technical Researchers Breakfast Wednesday 17th September 8am-8:50am - Classroom 1.219 (University Place)

Table 1	Dr Anna Melidoni Senior Editor BMC Biology, Springer Nature	Effective Publication
Table 2	Dr Meg Byrne Independent Cell Line Development and Platform Operations Consultant	Academia to Industry -Points to Consider
Table 3	Dr James Henstock Associate Professor in Bioengineering Northumbria University	Early career researchers - making your own path
Table 4	Prof Sue Kimber Professor of Stem Cells and Development University of Manchester	Writing successful grant applications
Table 5	Dr Alison Wilson Principal Consultant Cell Data Services	Regulatory aspects in Biotech
Table 6	Dr Ralph Adams UK Institute for Stats and Skills and University of Manchester	Research Technical Professionals career opportunities and pathways
Table 7	Dr Matthew Smart Lead Scientist Cell and Gene Therapy Catapult	Translation and manufacturing of commercially viable products
Table 8	Dr Rose Hugues European Patent Attorney Evolve Intellectual Property Limited	Protect, patent & partner: Mastering IP strategy for cell therapy
Table 9	Prof Glyn Stacey Director for the International Biobanking Initiative and SSCBio,	Latest standards in stem cell research and biotech

Sponsored by:

biotechne

 **iotaSciences**

ThermoFisher
SCIENTIFIC

 **WiCell**

Meet the Experts Early Career and Technical Researchers Breakfast

Table 1 - Effective publication



Dr Anna Melidoni
BMC Biology, Springer
Nature

Anna is a Senior Editor with BMC Biology, one of the selective journals of BMC, the first open-access publishing company and part of Springer Nature. She primarily handles Cell, Molecular, and Developmental Biology articles and she has a particular interest in Stem Cell Biology in relation to early embryology, tissue repair and Regenerative Medicine. Her work as an Editor involves making assessments of submitted articles pre peer-review, inviting suitable reviewers and making editorial decisions based on the reviewers' reports and the opinion of external editorial advisors. She also attends conferences connecting with researchers, commissions reviews articles and organizes thematic article Collections on important topics. Anna joined Springer Nature after being a Postdoctoral researcher for a few years, both in Greece, (University of Ioannina) and in the UK (University of Cambridge) working on various projects within the broad field of cell surface signalling and stem cell differentiation. While still a researcher, she was also a freelance consultant for PLOS Biology on stem cell-related articles. She holds a PhD in Molecular Biology from Queen Mary, University of London, UK and a BSc in Biology from the University of Crete, Greece.

Table 2 - Academia to Industry -Points to Consider



Dr Meg Byrne
Independent
Consultant

Meg is a leading expert in pluripotent stem cell engineering, specializing in CRISPR-based genome editing and scalable therapeutic cell line development. After beginning her career at NIBSC (MHRA), she spent over 12 years in academia at UCL, University of Bristol, and the Wellcome Sanger Institute, before transitioning into industry at bit.bio. There, she led the establishment and operation of their research-grade opti-ox™ cell line engineering pipeline, later building a regulatory-aligned therapeutic pluripotent stem cell development platform. Meg excels at translating academic protocols into robust, automated, and scalable systems, implementing phase-appropriate analytics and process controls to deliver regulatory-aligned engineered seed banks.

Table 3 - Early career researchers - making your own path



Dr James Henstock
Northumbria
University

James is currently Associate Professor of Bioengineering at Northumbria University in Newcastle and is an advocate for empowering early career researchers to take control over their career journey. As a postdoc at Keele in 2014 he decided to write a '5-year plan' for his career, which led to working in New York, a tenure-track fellowship at Liverpool University, and sending muscle organoids to the International Space Station. After being appointed to lecturer, he took time out to work in industry at a cultivated meat start up in Sydney, Australia. James is on BBSRC's People & Talent Strategy Advisory Panel, is a bioscience consultant for the European Space Agency, and a member of the REF 2029 pilot for People, Culture and Environment. This table will be about the practical steps you can take to plan your own unique career journey.

Table 4 - Writing successful grant applications



Prof. Sue Kimber
University of
Manchester

Sue is past Director of the MRC/EPSRC Centre for Doctoral Training in Regenerative Medicine and was Co-Director of the Northwest Embryonic Stem Cell Centre (NWESCC). She has over 30 years' experience in cell and developmental biology and 16 years' experience in stem cells, regenerative medicine, disease modelling and tissue engineering with >170 publications. Her lab has derived more than 50 human induced pluripotent stem cell (hiPSC) lines both from healthy individuals and those with disease conditions caused by mutations affecting the skeleton, kidney, nervous system and vasculature. They have developed and applied different 2D and 3D protocols to human embryonic stem cell and hiPSC, differentiating them to a range of tissues for understanding human development and for modelling genetic, often rare, diseases with a view to finding new drug targets. In 2019 she was awarded a Suffrage Science Award for her tissue engineering research by the Royal Society.

Table 5 - Regulatory aspects in Biotech



Dr Alison Wilson
Cell Data Services

Alison is an independent regulatory affairs consultant specialising in advanced therapy medicinal products. She has over 30 years' experience of regulatory affairs in industry with medicinal products, medical devices and ATMPs. Specialising in early-stage advice for academic groups and small spinouts, she has extensive experience with development of hESC-derived therapies for hearing loss and glaucoma, MSC for central nervous system and orthopaedic applications, dendritic cells in oncology immunotherapy, novel drug-device combinations and pro-drug delivery in oncology.

Alison has an MSc in stem cell biology and a PhD covering standardisation of cells for regenerative medicine and is a Fellow of TOPRA.


Table 6 - Research Technical Professionals career opportunities and pathways



Dr Ralph Adams
UK ITSS and University
of Manchester

Ralph is Head of the NMR service in the Department of Chemistry at the University of Manchester. He is a national leader in Technical Facility Operation: a former member of the EPSRC Research Technical Professionals Working Group and a founding and committee member of the UK Technology Specialists Network. He has consulted on issues of facility management, cost recovery and industry engagement, delivered numerous workshops at international meetings, summer schools, and in-house, and, as head of the NMR facility, has been responsible for securing >£10M capital for research equipment training many hundreds of research students. He is an expert in the development and application of NMR methodology and techniques. Ralph is secretary of the Royal Society of Chemistry's NMR Discussion Group and has contributed extensively to the organisation of national and international conferences. His research has had a significant influence on the ways in which solution state NMR is used in a broad range of fields, and he engages widely with the chemical, scientific instrument and pharmaceutical industries; his software has been downloaded >2000 times p.a. in each of the last 6 years and is included as standard in manufacturers' libraries.


Table 7 - Translation and manufacturing of commercially viable products



Dr Matthew Smart
Cell and Gene Therapy
Catapult

Matthew has been working in the pluripotent stem cell field for over 15 years. He gained his PhD at The Institute of Ophthalmology, University College London, as part of the London Project to Cure Blindness group, which developed a hESC-RPE-based cell therapy for AMD that showed great promise in FiH clinical trials. As a Lead Scientist at Cell and Gene Therapy Catapult, Matthew is active across all aspects of cell therapy translation, with specific expertise in pluripotent stem cell therapies. The SET team aims to develop next-generation manufacturing strategies for cell and gene therapy production, while helping to foster an environment that can best support developers as they move towards the clinic and beyond.

Table 8 - Protect, patent & partner: Mastering IP strategy for cell therapy



Dr Rose Hughes
Evolve Intellectual
Property Limited

Driven by a passion for science, Rose specialises in pharmaceutical and biotech patent strategy, combining scientific knowledge with practical IP solutions. She believes that IP strategy needs to be as innovative and forward-thinking as the science it seeks to protect. Her enthusiasm for the science shapes her approach to developing IP strategies that protect advanced therapeutics whilst creating competitive advantages for products and platforms. Rose has guided IP portfolios through every phase of development, from early discovery to on-market protection.

Table 9 - Latest standards in stem cell research and biotech



Prof Glyn Stacey
International
Biobanking Initiative
and SSCBio,

Glyn has an academic and applied background in microbiology and cancer research and until 2017 worked as a cell therapy specialist at the UK regulatory body (MHRA). From 2003, he was the founding Director for the UK Stem Cell Bank for human embryonic stem cells. Glyn's work has covered safety and quality issues in cell therapy, cells used for manufacturing purposes, development of novel cell-based assays genetic reference materials. Over more than 30 years, Glyn has also maintained a strong interest in improvement of cryopreservation methods and biobanking of various biological materials. He has been the Chair for the Society for Low Temperature Biology (www.sltb.info) and a member of drafting groups for guidance and standards on cell preservation. Glyn has also been a PI for several UK and EC funded stem cell research consortia and was a leading PI for the European iPSC bank project, EBiSC, for which he remains an expert advisor. He is an advisor for numerous UK, EU and Asian research institutes, and has been a special advisor on cell substrates to the WHO. He is also currently an expert advisor for stem cell institutes of the Chinese Academy of Sciences. Glyn is also the founding director for International Stem Cell Banking Initiative (www.iscbi.org) focusing on the application of hPSCs, with members in 28 countries.

Facilitator



Dr Lyn Healy
Independent

Lyn has worked in stem cell biology for over 40 years. She obtained her PhD at the Institute of Cancer Research, University of London where she worked for 18 years on haematopoietic stem cells and leukaemia. Following that, Lyn joined the UK Stem Cell Bank at the National Institute for Biological Standards and Control, part of the MHRA in 2003, working on Standardisation and Best Practice in the area of banking human Pluripotent Stem Cells and quality control. In 2015 Lyn joined the Francis Crick Institute and after working in the Haematopoietic Stem Cell Laboratory for a year she moved into the Human Embryo and Stem Cell Unit at the Francis Crick Institute, delivering services to the Crick scientific community until she left in February 2025.

Her experience includes participating in large infrastructure projects delivering quality control advice, cell lines and protocols. She is a member of the International Cell Line Authentication Committee, The International Society for Stem Cell Research, The International Society for Cell Therapy and is a member of the national committee for the ISO Technical Committee 276, sitting as an expert. Lyn is also a working group lead for the COST Action CorEUSstem, The European Network for Stem Cell Core Facilities.

The Pete Coffey Award



Professor Pete Coffey

Pete Coffey was a Professor at the UCL Institute of Ophthalmology and Executive Co-Director of Translation Center for Stem Cell Biology & Engineering UC Santa Barbara.

He was a pioneer of pluripotent stem cell derived cell therapy development, a true trail blazer and innovator of our field. Pete's research aimed to use stem cell technology to restore sight, prevent disease progression and ultimately improve the quality of life for patients with age-related macular degeneration (AMD) and other retinal and macular disorders. This work began with the serendipitous discovery of "black bits" in a culture of hESCs and led to the UK's first-in-human trial of these novel therapies.

Sadly, Pete passed away suddenly in June 2025 following a battle with a long-term illness. As a strong supporter of stem cell research, early career researchers (ECRs) and the re-establishment of the UK Stem Cell Network, the Community has launched the Pete Coffey Award in his honour. The Award will be presented to the Best Submitted ECR Abstract author, who will be invited to give their talk at this year's inaugural UK Stem Cell Network meeting this September.

More about Pete

Pete referred to himself as a "back of the eye guy" and you can hear him talk about his research as part of [Sheffield BioFest](#) from November 2023.

This research started at the University of Sheffield and continued when Pete moved to UCL in 2005. Pete established The London Project to Cure Blindness in 2007 with Moorfields Eye Hospital, to support the first clinical trial in the UK with a human embryonic stem cell derived product. His ground-breaking 2018 clinical study, published in [Nature Biotechnology](#), provided the first convincing evidence of restored vision using a transplanted pluripotent stem cell product.

His achievements, honours and awards have been plentiful and included the prestigious Estelle Doheny Living Tribute Award in 2009, Retinitis Pigmentosa International's Vision Award in 2009, the CIRM Leadership Award in 2010, and the New York Stem Cell Foundation Roberston Prize in 2011.

Pete lived it all: the highs and the lows and he did so while remaining incredibly honest and exceedingly generous with his time and knowledge.



Ioakeim Ampartzidis
University of Cambridge

Pete Coffey Award Winner

Dr Ioakeim Ampartzidis completed his PhD at UCL in the Neurulation Biomechanics (Galea) Lab, where he developed disease modelling platforms for studying spina bifida. Currently he is working as a postdoctoral research associate in the Hollfelder Lab at the University of Cambridge, studying planar cell polarity signalling during early embryonic development.

THE RESOURCE BEHIND THE RESEARCH



In addition to our stem cell catalog of over 1500 stem cell lines, WiCell provides **GMP karyotype, STR and FISH testing**, along with a range of non-GMP testing for a wide variety of cell types including hESCs, iPSCs, T-Cells, NK cells, and fibroblasts.

wicell.org

Always here for all of your stem cell and cell line testing needs



ORDER CELLS



TEST CELLS



STORE CELLS



BANK CELLS

Unlimited Discovery

Take your **single cell** analysis further with millions of cells per run.

SCALABLE
FIXATION-POWERED
INSTRUMENT-FREE TRANSCRIPTOMICS



From our bench to your bench

300,000+ citations of Proteintech products demonstrates what matters most: the success of its reagents in the hands of scientists.

Proteintech Product Range

- Primary antibodies against 13,500+ human targets
- **humankine**® GMP recombinant cytokines and growth factors
- **chromoteK** nanobody reagents
- **FlexAble** antibody labeling kits
- ELISA kits
- Magnetic cell separation systems
- Tag / Control antibodies
- CoraLite fluorescent-dye conjugated antibodies
- SignalBright chemiluminescent substrates
- NeutraKine neutralizing antibodies
- Tagged immunogens
- Secondary antibodies
- Phantom viability dyes
- Prestained protein markers
- IHC kits

Visit ptglab.com to browse the full product range.

When you need it all.

ptglab.com

IDT is sponsoring the UKSCN 2025 meeting!

Integrated DNA Technologies is thrilled to announce its sponsorship of the UK Stem Cell Network: 2025 Inaugural Scientific Conference, taking place in Manchester on the 16th and 17th of September 2025.

Meet us at the event and unlock your promo code for 10% off almost all stocked products!

- Next Generation Sequencing
- Functional Genomics
- PCR, qPCR, and dPCR
- CRISPR Gene Editing
- CGMP Manufacturing
- Gene Synthesis and Gene Fragments
- Custom Oligos
- Contract Manufacturing

10% off
Almost all product categories

FALL4TEN

Questions? I am here to help.

Sjaak van der Sar

Territory Sales Manager - Northern UK
svandersar@idtdna.com



Haier Biomedical

Building the Future of Gene Therapy? We're here to help.

160+ Countries & Regions | 600+ Intellectual Property Patents | 1 Billion+ End Users | 300+ Certified Medical Devices

Haier Biomedical | Lab Solutions That Work as Hard as You Do

Need storage you can trust? Want to simplify compliance? Or ready to scale without losing control?

At Haier Biomedical, we design lab-ready, future-proof solutions for biotech innovators who need more than just reliable equipment—we provide expertise, support, and speed.

- -150°C Cryogenic Freezers & LN₂ Storage Systems (-196°C)
- -86°C Ultra Low Temperature Freezers
- Refrigeration Systems for +4°C to -40°C
- Class II Biological Safety Cabinets
- High-Speed & Benchtop Centrifuges
- Automation for Biobanking & Cell Culture
- Smart, Scalable IoT Monitoring
- End-to-End Service & Validation

Whether you're managing fragile samples, planning a biobank, or tackling global health challenges, we can help you do it faster, smarter, and with confidence.

We're UK-based, fast to respond, and ready to support your next leap forward. Speak to us at **Stand 6** or contact our team today to get started.

Find more at

Web: www.haierbiomedical.co.uk
Call: 01932 780 070
Email: sales@haierbiomedical.co.uk



Haier Biomedical
Intelligent Protection of Life Science

TRANSFORM YOUR RESEARCH AND UNLOCK THE POWER OF 3D

About Us

We are a team of matrix biologists, cancer scientists, toxicologists, and biomaterial engineers who have worked together to develop an innovative, animal-free solution for 3D cell culture.

Our Mission

Our mission is to eliminate the need for animals and animal-derived materials in scientific research, by providing researchers with more reliable synthetic alternatives.

Our Technology

Our innovative self-assembling peptide hydrogel platform addresses all the current shortcomings of available in vitro models. Our hydrogels are entirely animal-free, have limited batch-to-batch variability, and can be customised to meet the needs of the user.

SCAN TO LEARN MORE:



Or drop us an email: info@peptimatrix.com



ANIMAL FREE
Our hydrogels are entirely synthetic, for more ethical science.



READY-TO-USE
Supplied ready-to-use and can be handled at room temperature.



REPRODUCIBLE
Because they're synthetic, they have limited batch variability.



VALIDATED
Each formulation is tried and tested across multiple cell types.



CUSTOMISABLE
Stiffness and composition can be customised to mimic different tissues.



VERSATILE
Compatible with ICC, RNA/DNA extraction, flow cytometry, and more.

A Member of PHC Group

When precision and stability are vital

Automatic culture control through In-line monitoring of glucose and lactate

LiCellMo **LiCellGrow**

Inaugural Meeting

University Place, Manchester

Tuesday 16th – Wednesday 17th September 2025



Poster No.	Present Author	Title
1	Aarushi Vaidya	Can early forebrain patterning/holoprosencephaly (HPE) be modelled in vitro using 2D and/or 3D human induced pluripotent stem cell models?
2	Adam Hirst	Enhanced genetic stability of human pluripotent stem cell cultures when single-cell passaging using eTeSR™
3	Ahmed Ramzy	Biphasic specification of the germline in the pig embryo
4	Alessandro Muratore	Novel insights on the role of CXCL12-CXCR4 signalling in hematopoietic development
5	Alessia Lofrano	Senescence in Cockayne Syndrome B patient-derived iPSCs: Implications of senescence resistant pathways in cellular reprogramming
6	Amal Khizer	Developing an iPSC model to understand the human endocardium and regeneration of the heart
7	Amr Moharram	Delineation of extra-embryonic lineage specification using human naïve pluripotent stem cell models
8	Angel Shiqing Ma	Mapping epithelial cell fate plasticity
9	Anna Lena Ellermann	Plakoglobin – a novel mechanoresponsive regulator of naïve pluripotency
10	Antigoni Gogolou	Arrayed CRISPR screening at the MRC-AZ-University of Cambridge Joint Functional Genomics Screening Laboratory (FGSL)
11	Antonius Plagge	Trappc9 mutation causes postnatal microcephaly, neural stem and progenitor cell loss and lipid droplet abnormalities – Establishment of a murine brain organoid model
12	Anzy Miller	NGN3 oscillatory expression controls the timing of human pancreatic endocrine stem cell differentiation
13	Aparna Sinha	Defining the chromatin interactomes of critical transcription factors in JAK2V617F myeloproliferative neoplasms
14	Basudha Basu	Using human iPSCs and organoids to model CEP290-related inherited retinal disease and develop splice-switching oligonucleotide therapies
15	Bethany Gallacher	Identifying mechanisms of Natural Killer (NK) cell mediated killing of leukaemia dormant cells
16	Chantelle Thimm	Evidence for conserved gene expression and biological processes operative in human podocytes and brain
17	Clara Andiazabal	Differential regulation of β -catenin and plakoglobin during the naïve to primed pluripotency transition
18	Dagmara Szmagłńska	Investigating the impact of genome damage and mitotic errors on human pluripotent stem cell fate
19	Danyun Zhao	Restoring BEST1 expression and chloride channel function in patient iPSC-Derived RPE
20	Drew Farr	TP63 regulates declining airway stem cell function during ageing
21	Eldo Galo	Long-term maintenance of adult limbal epithelial stem cells (LSCs) using Rock inhibitor (Ri) and assessment of its effects on cell identity
22	Elizabeth Haughey	A primary ciliary dyskinesia in vitro model using CRISPR-edited clonal primary epithelial stem cells
23	Eloise Moore	Establishment of models of aberrant ALK regulation during normal human sympathetic nervous system development

Inaugural Meeting

University Place, Manchester

Tuesday 16th – Wednesday 17th September 2025



Poster No.	Present Author	Title
24	Els F Halff	Using iPSC-derived forebrain organoids to explore mechanisms underlying accelerated telomere attrition in schizophrenia: effects of differentiation, maturation, genotype and environment
25	Emma Corbin	Applying the low adherence properties of the Cytocaf protein
26	Erica Harris	Using iPSC-derived neural progenitor cells to model the de novo MAX p.Arg60Gln variant underlying MAX-associated global development disorder
27	Fay Cooper	Human stem cell-derived enteric nervous system progenitor transplantation restores function responses in Hirschsprung disease patient-derived tissue
28	Federica F. Masieri	iPSC lines reprogrammed from healthy and osteoarthritic human fibroblast-like synoviocytes for in vitro OA modelling
29	Fehrish Sheikh	Investigating the impact of Alzheimer's Disease inflammatory microenvironment on the astrocytic $\alpha\beta3$ integrin / neuronal Thy-1 complex in vitro
30	Filipa Campos	Optimising culture conditions to promote hypoblast specification and improve the fidelity of human blastoids in modelling preimplantation development
31	Florence Woods	How are oscillatory protein dynamics decoded during human neurogenesis?
32	Gabriele Gelezauskaite	Investigating the consequences of mitotic errors in human pluripotent stem cells
33	Harry Moxom	Developing a 3D cartilage model for Acrodysostosis using human induced pluripotent stem cells
34	Heba Hamed Shkedif	Modelling disorders of the glycine cleavage system using human cellular models
35	Helena Raine	Characterization of patient iPSCs-derived striatal neurons with >140 CAG repeats over a 100 day-culture
36	Irene Zebochin	The role of vascular cells in rheumatoid arthritis pain
37	Jack Goodman	Defined matrix and Wnt agonists for human intestinal organoid culture
38	James Poulter	Nonsense, but not frameshift, truncating mutations result in Cyclin D2 stabilisation in an induced pluripotent stem cell model of MPPH
39	Jamie Bhagwan	hiPSC-derived cardiomyocytes for high through-put in vitro cardiac pharmacology and cardiotoxicity studies
40	Jennifer Stott	Arrayed synthetic gRNA libraries for high-throughput knockout screens in immortalized cell lines and iPSCs
41	Jess Orr	Primary human airway epithelial cell culture for cell transplantation
42	Jila Ajeian	Establishing CRISPR-engineered iPSC models to study primary ciliary dyskinesia
43	Jonathan A Williams	Upscaling manufacture of osteogenically differentiated mesenchymal stem cells using nanoscale vibration and microcarrier suspension culture
44	Jonathan Whitchurch	Efficient single-cell cloning of genome-edited human iPSCs: A user-friendly microfluidic approach
45	Kai Parkin	Dimensional and cellular insights: Direct PGCLC induction in Formative Stage (FS) and conventional H9 cells across 2D and 3D environments
46	Kasia Szymanska	Developing new treatments for cystic kidney disease

Inaugural Meeting

University Place, Manchester

Tuesday 16th – Wednesday 17th September 2025



Poster No.	Present Author	Title
47	Katy Boswell	Assessing the impact of neuroblastoma-linked lesions on human neural crest development
48	Kedar Bhosale	Elucidating the molecular mechanisms underlying Kabuki Syndrome Type 1 using iPSC-derived neuronal models
49	Keisuke Kaji	Precursor of chemically expanded hepatocytes (pre-cHep) with one-million-fold expansion potential and liver repopulation capacity
50	Kristupas Sirvydis	XIST supercomplexes- key actors in X-inactivation during early human embryonic development
51	Laura Fedele	Employing human iPSC-derived sympathetic neurons to investigate regulatory mechanisms of sympathetic neurons
52	Leona Ogene	A human PSC based platform for cartilage tissue engineering using GO reinforced hydrogels
53	Lili Bako	Standardisation and improvement of Apo-MS-C based therapeutic approaches using human embryonic stem cells
54	Liz Stewart	Differentiation of induced pluripotent stem cells (iPSCs) into ectoderm, mesoderm and endoderm lineages
55	Lydia Jestice	Investigating axonal transport in Charcot-Marie-Tooth disease Type 2A using a pluripotent stem cell-based model
56	Malgorzata Borkowska	Retinoic acid induced TET-independent global loss of DNA methylation in mouse embryonic stem cells
57	Marika Da Prato	Perlecan-conjugated laminin fragment as a next-generation culture substrate for human pluripotent stem cells
58	Marily Chasioti	Optimisation of lentiviral transduction in cultured airway basal epithelial cells
59	Marta Dorgnath	Uncovering the fundamental mechanisms of cardiac cell potential by understanding the regulation of NKX2-5 expression
60	Matteo Vietri Rudan	Human-specific stem cell regulation and the rise of new genomic functions through the lens of non-coding snoRNA host genes
61	Megan Douglas	Understanding the role of LIMP-2 in the lysosomal storage disorder Fabry Disease
62	Mercedes Vazquez	Modelling triple negative breast cancer in stem cell-derived organoids
63	Miriam Körsen	Autophagy alters the metabolic state of human embryonic stem cells
64	Najd Alzuabi	Investigating the molecular contribution of tensins in kidney tissue formation
65	Nele Liedtke	Establishing a human urine-based platform for modeling Bartter type 3 syndrome
66	Niamh McCarthy	Laminin-332 defects in airway epidermolysis bullosa and their correction with lentiviral therapy
67	Nicholas Kelly	Using a stem cell-derived disease model of Osteogenesis Imperfecta for the design of therapeutic gene editing strategies
68	Nicola Bates	Pluripotent stem cell generation and editing platform to support in vitro modelling of rare conditions at The University of Manchester
69	Oliver Davenport	Building better porous networks for bone tissue engineering
70	Oliver Rowley	Investigation of the role of DLG2 in cortical neural development using human brain organoids

Inaugural Meeting

University Place, Manchester

Tuesday 16th – Wednesday 17th September 2025



Poster No.	Present Author	Title
71	Owen Laing	Investigating the effects of aneuploidy on early human development using hPSC-based models
72	Patrizia Ferretti	Modelling neural pathology in Duchenne Muscular Dystrophy using iPSC-derived neural cells reveals defects in metabolic pathways and calcium signalling
73	Pietro Riccio	Development of PEGDA fluidgel platforms for targeted regenerative therapeutics
74	Rachel Steeg	The European Bank for Induced Pluripotent Stem Cells: a sustainable and worldwide iPSC repository
75	Rebecca Northeast	Driving experimental reproducibility and lot-to-lot biological consistency in human iPSC-derived cells enabled by opti-ox technology
76	Rosanne Mack	Investigating the molecular mechanisms underlying APOL1-mediated kidney disease-AMKD employing a unique human urine-derived podocyte cellular model
77	Ruth Williams	Dynamic regulatory programmes driving neural crest lineages are initiated from neural plate border stages
78	Sam Hobson	Organ-specific expression data guides choice of laminin for in vitro studies incorporating organ-on-a-chip platforms
79	Sara Cuvertino	Epigenome and transcriptome changes in KMT2D-related Kabuki syndrome Type 1 iPSCs, neuronal progenitors and cortical neurons
80	Sejla Pulo	Comparative analyses of mechanical stress and Angiotensin II – induced kidney injury employing a human urine-derived podocyte cell model
81	Selina Henriquez	Differentiation of iPSCs to functional iNK cells in suspension that effectively kill patient-derived tumouroid models
82	Shuruq Almuwallad	Heterozygous HNF1B mutation causes ureteric bud dysmorphogenesis in a human pluripotent stem cell organoid model
83	Srishti Bansal	Understanding mechanisms of cross talk between Tuberous sclerosis complex and the Notch signalling pathway
84	Sude Uyulgan	In vitro generation of human limb-like cells
85	Teresa Silva	Investigating Down syndrome-associated hindbrain developmental alterations using human organoids
86	Thorben A. Schlesinger	Investigating GRIK3 as a target for the treatment of Hepatocyte Nuclear Factor 1B-associated congenital kidney malformations
87	Yudan Ren	How do viruses cause birth defects? ---- The molecular mechanisms during early embryogenesis
88	Zac Sandy	Proteomic analysis of iPSC-derived neurons grown in microfluidic devices reveals a distinct axon proteome
89	Zaynab Butt	Investigating the use of allele-specific genome editing in a rare autosomal dominant form of blindness



Swift Analytical are proud distributors of the Nanocollect WOLF G2 microfluidic cell sorters; low pressure systems which enable highest viability sorting and plating for the most fragile stem cells.

Rinri
Therapeutics
Hearing. Restored.

Roslin^{CT}

Every cell therapy is unique, and so are our manufacturing solutions

Your innovative partner from Development to Commercialization



Contact us



MARRABIO
Versatile reagents for stem cell culture



ECM/Growth Factor proteins **Adherent Culture**
Low adherence coatings **Organoid culture**
Anticlumping reagents **Suspension Culture**

Come and see our poster for more information

TCS Biosciences Ltd Est. 1965

We supply affordable **reagents** for **organoids**, **cell** and **tissue culture**, and more...

Microcarriers: Smart MCs provide **customised**, **xeno-free** and **dissolvable microcarriers** tailored to specific cell types and applications. Our microcarriers enable efficient and streamlined cell culture while **minimising cell loss**, resulting in **cost-effective** and **high-yield** expansion of cells.

Hydrogels: Smart MCs deliver **fully defined**, **xeno-free** ECM Hydrogels, customisable for diverse applications like tissue modelling, spheroid generation, and wound healing. Engineered for precision and versatility, our hydrogels **optimise cell growth**, offering a controlled, reproducible solution for advanced biomedical applications.

Microfluidics: By integrating Smart MCs' microfluidic technologies into your research, you gain access to cutting-edge tools that **enhance precision, efficiency, and reproducibility** in.

Recombinant Proteins: We have developed **high-quality** recombinant cytokines and growth factors, utilising 15 years of manufacturing expertise. They are designed to provide the scientific research markets products at **competitive prices**. Our **animal-free** recombinant proteins can be supplied to meet individual research demands, offering **bespoke solutions**.

Cytocaf: MarraBio's proprietary engineered Cytocaf proteins provide an **easy to use, ultra stable, scalable** and **xeno-free** alternative to the ECM proteins and growth factors used in mammalian cell culture.



Tel: 01296 714222
Email: sales@tcsgroup.co.uk
Web: www.tcsbiosciences.co.uk

bit.bio
THE CELL CODING COMPANY



UK Stem Cell Network

THANK YOU